BACKGROUND: Peak serum concentrations of methotrexate (MTX) have been reported to correlate with outcome in osteosarcoma (OS). Modification of the MTX dose to achieve peak levels between 700 and 1,000 micromol/L has been recommended. The goal of the study was to assess whether there is a correlation between histologic necrosis of the tumor and/or prognosis with peak MTX serum concentration. PROCEDURE: Treatment included multi-agent adjuvant chemotherapy, including high-dose MTX (12 g/m2). Peak MTX levels were drawn following a 4-hr infusion. Histologic evaluation for percent necrosis was done at the time of definitive resection. RESULTS: The median peak MTX level (n = 52 patients) was 1,060 micromol/L (range: 410-4,700 micromol/L), with significant intra-patient and inter-patient variability. Fifty-eight percent of the levels were 1,000 micromol/L or higher. Response to pre-operative chemotherapy was: 18% Grade I necrosis, 35% Grade II, 31% Grade III, and 16% Grade IV. No significant association was found between the mean peak MTX levels and necrosis (P = 0.44). Event-free survival (EFS) for the 48 patients with non-metastatic disease at diagnosis was 76% at 4 years of follow-up, with no association between the mean peak MTX level and EFS (P = 0.24). CONCLUSIONS: The absence of a demonstrable correlation between peak MTX levels and histologic necrosis or EFS may suggest that most patients achieve therapeutic levels when MTX is given at a dose of 12 g/m(2). The significant degree of intra-patient variability in peak levels poses a dilemma for pharmacokinetic adjustment. Continued use of HD-MTX in all patients, rather than dose adapted therapy, may be justified. Copyright 2005 Wiley-Liss, Inc.
BACKGROUND: Peak serum concentrations of methotrexate (MTX) have been reported to correlate with outcome in osteosarcoma (OS). Modification of the MTX dose to achieve peak levels between 700 and 1,000 micromol/L has been recommended. The goal of the study was to assess whether there is a correlation between histologic necrosis of the tumor and/or prognosis with peak MTX serum concentration. PROCEDURE: Treatment included multi-agent adjuvant chemotherapy, including high-dose MTX (12 g/m2). Peak MTX levels were drawn following a 4-hr infusion. Histologic evaluation for percent necrosis was done at the time of definitive resection. RESULTS: The median peak MTX level (n = 52 patients) was 1,060 micromol/L (range: 410-4,700 micromol/L), with significant intra-patient and inter-patient variability. Fifty-eight percent of the levels were 1,000 micromol/L or higher. Response to pre-operative chemotherapy was: 18% Grade I necrosis, 35% Grade II, 31% Grade III, and 16% Grade IV. No significant association was found between the mean peak MTX levels and necrosis (P = 0.44). Event-free survival (EFS) for the 48 patients with non-metastatic disease at diagnosis was 76% at 4 years of follow-up, with no association between the mean peak MTX level and EFS (P = 0.24). CONCLUSIONS: The absence of a demonstrable correlation between peak MTX levels and histologic necrosis or EFS may suggest that most patients achieve therapeutic levels when MTX is given at a dose of 12 g/m(2). The significant degree of intra-patient variability in peak levels poses a dilemma for pharmacokinetic adjustment. Continued use of HD-MTX in all patients, rather than dose adapted therapy, may be justified. Copyright 2005 Wiley-Liss, Inc.
Authors: Andrew N Keller; Sidonia B G Eckle; Weijun Xu; Ligong Liu; Victoria A Hughes; Jeffrey Y W Mak; Bronwyn S Meehan; Troi Pediongco; Richard W Birkinshaw; Zhenjun Chen; Huimeng Wang; Criselle D'Souza; Lars Kjer-Nielsen; Nicholas A Gherardin; Dale I Godfrey; Lyudmila Kostenko; Alexandra J Corbett; Anthony W Purcell; David P Fairlie; James McCluskey; Jamie Rossjohn Journal: Nat Immunol Date: 2017-02-06 Impact factor: 25.606
Authors: Elizabeth Fox; Christine Busch; Alexander DeBernardo; Blair Segers; Joseph Gottschalk; Richard Womer; Naomi Balamuth; Rochelle Bagatell; Frank Balis Journal: Cancer Chemother Pharmacol Date: 2021-03-07 Impact factor: 3.333
Authors: Marta Hegyi; Agnes Gulácsi; Edit Cságoly; Katalin Csordás; Olivér T Eipel; Dániel J Erdélyi; Judit Müller; Karolina Nemes; Orsolya Lautner-Csorba; Gábor T Kovács Journal: J Cancer Res Clin Oncol Date: 2012-06-01 Impact factor: 4.553